Please login to the form below

Not currently logged in
Email:
Password:

Astellas acquires European rights for Eligard

MediGene sells full European marketing and distribution rights to Eligard for €25m and ongoing royalties

Germany's first publicly-traded biotechnology company, MediGene, has sold full European marketing and distribution rights to its hormone-dependent prostate cancer drug, Eligard (leuprolide acetate) to Astellas Pharma Europe. Previously, Astellas was MediGene's European marketing partner for Eligard, having acquired these rights from TOLMAR Therapeutics in 2001.

The agreement states that Astellas will pay MediGene €25m for the Eligard licence over the next six to 12 months, in three tranches as the steps of transfer of the rights are concluded. MediGene will also receive single-digit royalties on future net European product sales.

In return, the biotech will relinquish all future costs, obligations and risks associated with the supply of Eligard to Astellas and all future procurement costs and licence payments to TOLMAR will cease within the next months.

According to Arnd Christ, MediGene's chief financial officer: "This is an excellent deal for MediGene, both in financial and strategic terms. It not only reflects the full net present value of all future Eligard revenues according to the previous deal structure, but also provides us with significant and non-dilutive financing in a very tough capital markets environment.

"Furthermore, the structure of the deal allows MediGene to continue to benefit from the increasing revenue from Eligard, which was not possible under the previous structure. The significant improvement of our balance sheet and the simplification of the Eligard deal structure allow us to fund growth opportunities and thus strengthen the future pipeline of the company."

21st July 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe's leading hub for life sciences innovation...

Infographics